Nova Mentis Will Test Potential Psychedelic Treatment in Animal Model
Nova Mentis is expanding its preclinical pipeline to test a psychedelic treatment known as PLZ-1013 in an animal model of fragile X syndrome. The psychedelic compound, psilocybin, is being investigated as a potential behavioral therapy for fragile X. Researchers at the Canada-based company are collaborating with…